U.S. proposes rule tightening review of biotech licensing deals with Chinese firms

The U.S. is preparing to issue a proposed rule that would place additional scrutiny on outbound licensing agreements between American biotech firms and Chinese companies. The measure aims to increase oversight of technology transfers that could have national security implications.

In related health policy news, Belgium has declined to provide coverage for the diabetes drug Mounjaro, and Roche's chief executive criticized Europe for lagging in pharmaceutical innovation and support.

Additionally, several telehealth providers have begun offering off‑label prescriptions of GLP‑1 medications, both branded and compounded, to address alcohol use disorder and other addictions, reflecting a response to an unmet medical need as early evidence of benefit emerges.